HUTCHMED (China) Limited Stock Nasdaq

Equities

HCM

US44842L1035

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
18.41 USD +0.88% Intraday chart for HUTCHMED (China) Limited +11.91% +1.66%
Sales 2024 * 681M Sales 2025 * 836M Capitalization 3.14B
Net income 2024 * -109M Net income 2025 * -6M EV / Sales 2024 * 4.32 x
Net cash position 2024 * 199M Net cash position 2025 * 306M EV / Sales 2025 * 3.39 x
P/E ratio 2024 *
-27.2 x
P/E ratio 2025 *
571 x
Employees 1,988
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on HUTCHMED (China) Limited

1 day+0.88%
1 week+11.91%
Current month+9.58%
1 month+12.32%
3 months+35.87%
6 months+3.84%
Current year+1.66%
More quotes
1 week
16.21
Extreme 16.21
18.73
1 month
16.07
Extreme 16.07
18.73
Current year
11.93
Extreme 11.9343
19.40
1 year
10.68
Extreme 10.68
20.73
3 years
7.39
Extreme 7.39
43.94
5 years
7.39
Extreme 7.39
43.94
10 years
7.39
Extreme 7.39
43.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 04-12-31
Director of Finance/CFO 57 08-06-30
Chief Tech/Sci/R&D Officer 59 21-12-31
Members of the board TitleAgeSince
Chairman 72 99-12-31
Director/Board Member 73 17-02-28
Director/Board Member 70 16-07-31
More insiders
Date Price Change Volume
24-04-24 18.41 +0.88% 57,768
24-04-23 18.25 +7.73% 121,697
24-04-22 16.94 +2.67% 148,847
24-04-19 16.5 +0.86% 61,049
24-04-18 16.36 -0.55% 187,961

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.68 USD
Average target price
5.412 USD
Spread / Average Target
+47.09%
Consensus

Quarterly revenue - Rate of surprise